¿Podemos utilizar la apolipoproteína B en la toma de decisiones para la intervención en el riesgo cardiovascular de pacientes con triglicéridos elevados?

Grundy, 2002, Low density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy, Circulation, 106, 2526, 10.1161/01.CIR.0000038419.53000.D6 De Backer, 2003, Third Join Task Force OF European and Other Societies on Cardiovascular Disease prevention in Clinical Practice, Eur J Cardio Prev Rev, 10, S1, 10.1097/00149831-200312001-00001 Grundy, 2004, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Grundy, 1995, Role of low-density lipoproteins in atherogenesis and development of coronary heart disease, Clin Chem, 41, 139, 10.1093/clinchem/41.1.139 Gordon, 1981, Lipoproteins, cardiovascular disease and death. The Framingham Study, Arch Intern Med, 141, 1128, 10.1001/archinte.1981.00340090024008 Assmann, 1998, The Münster Heart Study (PROCAM), Eur Heart J, 19, A2 Castelli, 1986, Incidence of coronary heart disease and lipoprotein levels. The Framingham Study, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 2001, Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Bachorik, 1995, National Cholesterol Education Program Recommendations for measurement of low-density cholesterol: Executive summary, Clin Chem, 41, 1414, 10.1093/clinchem/41.10.1414 Friedewald, 1972, Estimation of the concentration of low-density cholesterol in plasma, without the use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 McNamara, 1990, Calculated values of low-density lipoprotein in the assessment of lipid abnormalities and coronary disease risk, Clin Chem, 36, 36, 10.1093/clinchem/36.1.36 Rubiés-Prat, 1993, Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus, Diabetes Care, 16, 1081, 10.2337/diacare.16.8.1081 Snidermann, 2002, How, when, and why to use apolipoprotein B in clinical practice, Am J Cardiol, 90, 48i, 10.1016/S0002-9149(02)02633-4 Nauck, 2002, Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation, Clin Chem, 48, 236, 10.1093/clinchem/48.2.236 Harper, 2010, Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?, Mayo Clin Proc, 85, 440, 10.4065/mcp.2009.0517 Assmann, 1983, Quantification high density lipoprotein cholesterol by precipitation with fosfotungstic acid/MgCl, Clin Chem, 29, 2026, 10.1093/clinchem/29.12.2026 Myers, 2000, Standardization of lipid and lipoprotein measurement, 717 Marcovina, 1994, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, IV: comparability of apolipoprotein B values by use of international reference materials, Clin Chem, 40, 586, 10.1093/clinchem/40.4.586 Contois, 2009, Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clin Chem, 55, 407, 10.1373/clinchem.2008.118356 Brunzell, 2008, American Diabetes Association, American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Diabetes Care, 31, 811, 10.2337/dc08-9018